AstraZeneca PLC (AZN) Return on Equity (ROE): 21.95%
Is AstraZeneca PLC’s return on equity (ROE) high or low?
AstraZeneca PLC's return on equity (ROE) of 21.95% is 58% above its 5-year average of 13.86%, near the high end of its 5-year range (0.29%–21.95%).
As of Sunday, June 14, 2026. 14.56% above its 12-month average of 19.16%.
AZN Return on Equity (ROE) Chart
AZN Average Return on Equity (ROE) Chart
AZN Current vs Average Return on Equity (ROE) Chart
AZN Return on Equity (ROE) Metrics
RETURN ON EQUITY (ROE)
21.95%
RETURN ON EQUITY (ROE) AVG TTM
19.16%
RETURN ON EQUITY (ROE) AVG 3Y
15.60%
RETURN ON EQUITY (ROE) AVG 5Y
13.86%
RETURN ON EQUITY (ROE) AVG 10Y
15.41%
RETURN ON EQUITY (ROE) AVG 15Y
18.15%
RETURN ON EQUITY (ROE) AVG 20Y
22.72%
CURRENT VS TTM AVG
+14.56%
CURRENT VS 3Y AVG
+40.68%
CURRENT VS 5Y AVG
+58.37%
CURRENT VS 10Y AVG
+42.44%
CURRENT VS 15Y AVG
+20.92%
CURRENT VS 20Y AVG
-3.39%
AZN Competitors' Return on Equity (ROE)
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| AstraZeneca PLC (AZN) | $277.22B | 21.95% | 19.16% | 15.60% | 13.86% |
| Merck & Co., Inc. (MRK)vs › | $294.03B | 19.48% | 35.83% | 26.05% | 27.71% |
| Amgen Inc. (AMGN)vs › | $191.70B | 84.87% | 79.33% | 111.35% | 101.76% |
| UnitedHealth Group Incorporated (UNH)vs › | $371.00B | 11.59% | 14.18% | 19.86% | 21.18% |
| Thermo Fisher Scientific Inc. (TMO)vs › | $174.42B | 13.21% | 12.70% | 13.51% | 15.24% |
| Gilead Sciences, Inc. (GILD)vs › | $155.93B | 39.19% | 20.05% | 21.63% | 19.46% |
| Abbott Laboratories (ABT)vs › | $153.59B | 12.06% | 20.32% | 18.59% | 17.97% |
| AbbVie Inc. (ABBV)vs › | $402.35B | 13.23% | -0.29% | 28.74% | 37.53% |
| Pfizer Inc. (PFE)vs › | $149.38B | 8.31% | 9.04% | 13.32% | 16.07% |
| Intuitive Surgical, Inc. (ISRG)vs › | $145.58B | 17.05% | 15.07% | 13.91% | 13.46% |
Return Analysis
ROE
21.9%
ROA
9.1%
AstraZeneca PLC Return on Equity (ROE) Formula & Definition
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
AstraZeneca PLC Return on Equity (ROE) FAQ
- What is the return on equity (ROE) for AstraZeneca PLC (AZN)?
- The return on equity (ROE) for AZN stock is 21.95%.
- Is AstraZeneca PLC's return on equity (ROE) high or low?
- AstraZeneca PLC's return on equity (ROE) of 21.95% is 58% above its 5-year average of 13.86%, near the high end of its 5-year range (0.29%–21.95%).
- What is the TTM average return on equity (ROE) for AstraZeneca PLC (AZN)?
- The TTM average return on equity (ROE) for AZN stock is 19.16%.
- What is the 3Y average return on equity (ROE) for AstraZeneca PLC (AZN)?
- The 3Y average return on equity (ROE) for AZN stock is 15.60%.
- What is the 5Y average return on equity (ROE) for AstraZeneca PLC (AZN)?
- The 5Y average return on equity (ROE) for AZN stock is 13.86%.
- What is the 10Y average return on equity (ROE) for AstraZeneca PLC (AZN)?
- The 10Y average return on equity (ROE) for AZN stock is 15.41%.
- What is the 15Y average return on equity (ROE) for AstraZeneca PLC (AZN)?
- The 15Y average return on equity (ROE) for AZN stock is 18.15%.
- What is the 20Y average return on equity (ROE) for AstraZeneca PLC (AZN)?
- The 20Y average return on equity (ROE) for AZN stock is 22.72%.
AstraZeneca PLC Return on Equity (ROE) History
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-12-31 | 21.07% |
| 2024-12-31 | 17.25% |
| 2023-12-31 | 15.21% |
| 2022-12-31 | 8.88% |
| 2021-12-31 | 0.29% |
| 2020-12-31 | 20.46% |
| 2019-12-31 | 10.17% |
| 2018-12-31 | 17.28% |
| 2017-12-31 | 20.06% |
| 2016-12-31 | 23.56% |
| 2015-12-31 | 15.28% |
| 2014-12-31 | 6.28% |
| 2013-12-31 | 11.01% |
| 2012-12-31 | 26.29% |
| 2011-12-31 | 42.66% |
| 2010-12-31 | 34.69% |
| 2009-12-31 | 36.40% |
| 2008-12-31 | 38.34% |
| 2007-12-31 | 37.86% |
| 2006-12-31 | 39.49% |
| 2005-12-31 | 34.61% |
| 2004-12-31 | 25.44% |
| 2003-12-31 | 23.04% |
| 2002-12-31 | 25.40% |
| 2001-12-31 | 30.31% |
| 2000-12-31 | 26.67% |
| 1999-12-31 | 11.09% |
| 1998-12-31 | 28.40% |
| 1997-12-31 | 33.80% |
| 1996-12-31 | 31.61% |
Related Metrics
About AstraZeneca PLC
AstraZeneca PLC operates as a global biopharmaceutical leader, dedicated to the entire process of bringing prescription medicines to market, from their initial discovery and development through manufacturing and commercialization. The company's extensive portfolio of treatments, including prominent examples like Tagrisso, Farxiga, and Symbicort, addresses critical areas such as cardiovascular, renal, metabolic, and oncological conditions. Furthermore, it provides essential solutions for COVID-19 and various rare diseases, with products like Vaxzevria and Soliris. AstraZeneca engages with primary and specialty care physicians worldwide, facilitating distribution through a robust network of representatives and local offices across the United Kingdom, continental Europe, the Americas, Asia, Africa, and Australasia. The firm actively drives innovation through strategic collaborations, partnering with entities such as Neurimmune AG for the development and commercialization of NI006, BenevolentAI for systemic lupus erythematosus drug discovery, Lunit for AI-powered digital pathology risk assessment in NSCLC, and Absci Corporation for AI-driven oncology target identification. Founded in 1992, the company was initially known as Zeneca Group PLC, subsequently rebranding to AstraZeneca PLC in April 1999, and maintains its headquarters in Cambridge, United Kingdom.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Pascal Claude Roland Soriot